Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Liabilities and Shareholders Equity: 2015-2025

Historic Liabilities and Shareholders Equity for Spyre Therapeutics (SYRE) over the last 10 years, with Sep 2025 value amounting to $504.6 million.

  • Spyre Therapeutics' Liabilities and Shareholders Equity rose 19.83% to $504.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 billion, marking a year-over-year increase of 31.73%. This contributed to the annual value of $608.5 million for FY2024, which is 77.99% up from last year.
  • Latest data reveals that Spyre Therapeutics reported Liabilities and Shareholders Equity of $504.6 million as of Q3 2025, which was down 6.35% from $538.8 million recorded in Q2 2025.
  • In the past 5 years, Spyre Therapeutics' Liabilities and Shareholders Equity registered a high of $608.5 million during Q4 2024, and its lowest value of $52.5 million during Q1 2023.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $436.1 million (2024), whereas its average is $401.1 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first crashed by 49.17% in 2022, then soared by 829.60% in 2024.
  • Spyre Therapeutics' Liabilities and Shareholders Equity (Quarterly) stood at $109.9 million in 2021, then slumped by 35.28% to $71.1 million in 2022, then spiked by 380.52% to $341.9 million in 2023, then surged by 77.99% to $608.5 million in 2024, then climbed by 19.83% to $504.6 million in 2025.
  • Its Liabilities and Shareholders Equity was $504.6 million in Q3 2025, compared to $538.8 million in Q2 2025 and $569.8 million in Q1 2025.